Locoregional therapy for cholangiocarcinoma

@article{Kuhlmann2013LocoregionalTF,
  title={Locoregional therapy for cholangiocarcinoma},
  author={Jan B. Kuhlmann and H. E. Blum},
  journal={Current Opinion in Gastroenterology},
  year={2013},
  volume={29},
  pages={324–328}
}
Purpose of review Cholangiocarcinoma has a poor prognosis. Surgical resection offers the only curative option and usually requires a major hepatic resection in addition to resection of the cholangiocarcinoma. Unfortunately, curative resection is possible in only about 30% of patients due to locally advanced disease, distant metastases or comorbidity in elderly patients. Even after resection, the recurrence rate is approximately 60%, resulting in a low 5-year overall survival (OS). In… 

Locoregional Therapy for Cholangiocarcinoma

A review of emerging technologies and their potential role in treating cholangiocarcinoma explores locoregional therapies with thermal ablation and transarterial techniques.

The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma

The present review describes the current evidence of the interventional treatments in the management of the ICC and suggests interventional procedures available to increase the future liver reserve before surgery were analyzed.

Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center.

Prognostic Impact of Tumor Growth Type on 7th AJCC Staging System for Intrahepatic Cholangiocarcinoma: a Single-Center Experience of 659 Cases

Growth type of IHCC seems to be essential for determining tumor stage, and clear prognostic contrast was achieved among T1–3 stages with the redefined staging system with tumor growth types and risk factors.

Diagnosis and systemic therapy for hepatobiliary cancer

In HCC, therapy with the multikinase inhibitor sorafenib is established and new second-line therapies are expected, and gemcitabine and cisplatin is standard in first-line therapy.

Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center

The presence of liver cirrhosis A/B should not prevent patients with a good Eastern Cooperative Oncology Group Performance Status score from receiving tumor resection or chemotherapy from receiving chemotherapy, and patients’ general condition seems to be of more prognostic value in the treatment of iCCA than the presence of Cirrhosis.

Liver-Directed Therapy for Hepatic Malignancies

This short review focuses on ablation and hepatic artery–directed therapies, and aims to provide a brief overview, indications for therapy, and outcomes from selected trials.

Intrahepatic Cholangiocarcinoma.

A global understanding to the management of intrahepatic cholangiocarcinoma (ICC) can help the interventional radiologist understand the role of locoregional therapies such as ablation, transarterial chemoembolization, and radioembolized in the managementof ICC.

References

SHOWING 1-10 OF 20 REFERENCES

Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.

Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma.

RFA may provide successful local tumor control in patients with primary intrahepatic cholangiocarcinomas of intermediate (3-5 cm) or small (< 3 cm) diameter, and percutaneous radiofrequency ablation was achieved for 15 of the 17 tumors, all smaller than 5 cm in diameter.

Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success

TACE is a palliative and safe treatment option for patients with unresectable CCC and prognostic factors governing treatment success, including initial tumor response, high tumor vascularity and Child‐Pugh class A were statistically significant factors for patient's survival.

Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival

Radioembolization is an effective and safe option for patients with unresectable ICC and predictors for prolonged survival are performance status, tumor burden, and RECIST response.

Adjuvant Transcatheter Arterial Chemoembolization for Intrahepatic Cholangiocarcinoma after Curative Surgery: Retrospective Control Study

Adjuvant TACE after radical surgery was associated with better survival among the ICC patients with early recurrence, indicating that TACE could not delay recurrence but could prolong the OS of patients withEarly recurrence.

Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy

This is the first study demonstrating that treatment of patients suffering from intrahepatic CCC with iDEB-TACE is safe in patients with normal liver function, and results in a prolongation of PFS and OS.

Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study

Patients with localized CCA who are selected for CDS are strongly associated with improved survival, with rates approaching that found in single institution studies, however, many patients with localized tumors do not receive potentially curative cancer-directed surgery.

Palliation of hepatic tumors.

Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma

SBRT shows promise as an effective local therapy for properly-selected patients with cholangiocarcinoma and further follow-up is needed to better quantify the risk of late complications associated with SBRT.